)
Mumbai-based Cipla Global, the multinational pharmaceutical and biotechnology company, has entered into a commercial collaboration with S&D Pharma in the Czech Republic and Slovakia.
Cipla, which is led by Y K Hamied (pictured) will drive its respiratory products portfolio in both European countries through a company sales team.
S&D Pharma, which represents other global drug companies in the two countries, will physically distribute all products, including those to treat respiratory ailments. The portfolio will increase over the next few years.
In the near future, once regulatory and reimbursement approvals are in place, a Salmeterol-Fluticasone fixed combination will be launched in both markets under the Fullhale name.
Apart from Croatia, where the combination is already available under the name of Duohal, Cipla recently launched the product in Germany and Sweden. On Monday, Cipla shares closed at Rs 563.4, up by 1.1 per cent on the BSE. Last week, Cipla had announced it’s wholly owned subsidiary, Medispray Laboratories, would acquire two manufacturing undertakings worth Rs 100 crore.
The first facility, at Goa, is owned by Okasa Pvt Ltd and the second, at Satara (Maharashtra), by Okasa Pharma.
